|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 12/11/18 Emmaus Life Sciences, Inc. 10-K 9/30/18 77:6.9M S2 Filings LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 930K
2: EX-10.13 Material Contract HTML 54K
3: EX-10.14 Material Contract HTML 53K
4: EX-10.15 Material Contract HTML 37K
5: EX-23.1 Consent of Experts or Counsel HTML 21K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 26K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 26K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 22K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 22K
16: R1 Document and Entity Information HTML 58K
17: R2 Consolidated Balance Sheets HTML 126K
18: R3 Consolidated Balance Sheets (Parenthetical) HTML 49K
19: R4 Consolidated Statements of Operations HTML 78K
20: R5 Consolidated Statements of Changes in Equity HTML 104K
21: R6 Consolidated Statements of Cash Flows HTML 119K
22: R7 Consolidated Statements of Cash Flows HTML 24K
(Parenthetical)
23: R8 Nature of Operations HTML 32K
24: R9 Summary of Significant Accounting Policies HTML 90K
25: R10 Accounts Receivable, Net HTML 27K
26: R11 Long - Term Borrowings and Other Note Payables HTML 26K
27: R12 Acquisition HTML 47K
28: R13 Stockholders' Equity HTML 207K
29: R14 Convertible Preferred Stock HTML 39K
30: R15 Income Taxes HTML 67K
31: R16 Related Party Transactions HTML 29K
32: R17 Loss Per Share HTML 37K
33: R18 Commitments and Contingent Liabilities HTML 33K
34: R19 Significant Customers HTML 23K
35: R20 Subsequent Events HTML 32K
36: R21 Summary of Significant Accounting Policies HTML 165K
(Policies)
37: R22 Summary of Significant Accounting Policies HTML 26K
(Tables)
38: R23 Accounts Receivable, Net (Tables) HTML 28K
39: R24 Acquisition (Tables) HTML 46K
40: R25 Stockholders' Equity (Tables) HTML 176K
41: R26 Income Taxes (Tables) HTML 67K
42: R27 Loss Per Share (Tables) HTML 37K
43: R28 Commitments and Contingent Liabilities (Tables) HTML 28K
44: R29 Nature of Operations (Details Narrative) HTML 32K
45: R30 Summary of Significant Accounting Policies HTML 32K
(Details )
46: R31 Summary of Significant Accounting Policies HTML 31K
(Details Narrative)
47: R32 Summary of Significant Accounting Policies HTML 71K
(Details Narrative 1)
48: R33 Accounts Receivable, Net (Details) HTML 29K
49: R34 Long - Term Borrowings and Other Note Payables HTML 48K
(Details Narrative)
50: R35 Acquisition (Details) HTML 67K
51: R36 Acquisition (Details 1) HTML 29K
52: R37 Acquisition (Details Narrative) HTML 57K
53: R38 Stockholders' Equity (Details) HTML 34K
54: R39 Stockholders' Equity (Details 1) HTML 27K
55: R40 Stockholders' Equity (Details 2) HTML 56K
56: R41 Stockholders' Equity (Details 3) HTML 123K
57: R42 Stockholders' Equity (Details 4) HTML 50K
58: R43 Stockholders' Equity (Details 5) HTML 34K
59: R44 Stockholders' Equity (Details 6) HTML 43K
60: R45 Stockholders' Equity (Details 7) HTML 63K
61: R46 Stockholders' Equity (Details Narrative) HTML 215K
62: R47 Stockholders' Equity (Details Narrative 1) HTML 101K
63: R48 Convertible Preferred Stock (Details Narrative) HTML 59K
64: R49 Income Taxes (Details) HTML 45K
65: R50 Income Taxes (Details 1) HTML 40K
66: R51 Income Taxes (Details 2) HTML 44K
67: R52 Income Taxes (Details 3) HTML 42K
68: R53 Income Taxes (Details Narrative) HTML 36K
69: R54 Related Party Transactions (Details Narrative) HTML 61K
70: R55 Loss Per Share (Details) HTML 48K
71: R56 Commitments and Contingent Liabilities (Details) HTML 25K
72: R57 Commitments and Contingent Liabilities (Details HTML 42K
Narrative)
73: R58 Significant Customers (Details Narrative) HTML 31K
74: R59 Subsequent Events (Details Narrative) HTML 60K
76: XML IDEA XML File -- Filing Summary XML 131K
75: EXCEL IDEA Workbook of Financial Reports XLSX 100K
10: EX-101.INS XBRL Instance -- mynd-20180930 XML 1.87M
12: EX-101.CAL XBRL Calculations -- mynd-20180930_cal XML 199K
13: EX-101.DEF XBRL Definitions -- mynd-20180930_def XML 782K
14: EX-101.LAB XBRL Labels -- mynd-20180930_lab XML 1.28M
15: EX-101.PRE XBRL Presentations -- mynd-20180930_pre XML 1.00M
11: EX-101.SCH XBRL Schema -- mynd-20180930 XSD 198K
77: ZIP XBRL Zipped Folder -- 0001615774-18-014245-xbrl Zip 174K
Exhibit 10.13
SUBSCRIPTION AGREEMENT FOR SHARES OF
COMMON STOCK
AND COMMON STOCK PURCHASE WARRANTS
This SUBSCRIPTION Agreement (this “Agreement”) is made as of September 21, 2018 by, and between MYnd Analytics, Inc., a Delaware corporation (the “Company”), and the investors listed on Schedule A hereto (each, an “Investor,” and collectively, the “Investors”).
WITNESSETH
In consideration for the mutual promises and covenants herein, the parties agree as follows:
WHEREAS, the Company is offering, in a private placement of investment units for $1.85, consisting of shares of its Common Stock (“Common Stock”), par value $0.001 per share (the “Shares”) and Common Stock Purchase Warrants (“Warrants”) to purchase shares of Common Stock in a private placement to accredited investors pursuant to a Confidential Offering Memorandum dated September 20, 2018; and
WHEREAS, the undersigned desires to subscribe for and purchase the number of Shares set forth on Schedule A hereto.
Section 1 – Purchase and Sale of SHARES
1.1 Purchase and Sale of Shares. The Company has authorized the issuance and sale, in accordance with the terms hereof, of Shares and Warrants, provided that one (1) Warrant shall be issued for every one (1) Share. On the terms and subject to the conditions set forth in this Agreement, at the Closings (as defined below), the Company agrees to issue to each Investor, and each Investor agrees to purchase from the Company, the quantity of Shares and Warrants in the amount set forth on Schedule A at a price per Share and Warrant of $1.85 USD. The Company will sell Shares and Warrants to more than one Investor, each of whom will enter into Subscription Agreement substantially identical to this one.
1.2 Closings.
(a) Initial Closing. The initial purchase and sale of the Shares and Warrants shall take place at a closing (the “Initial Closing”) which shall take place remotely via exchange of documents and signatures at 10:00 a.m. Eastern Time on the business day immediately following execution and delivery of this Agreement, or at such other place and time as may be agreed to among the Company and the Investors. At the Initial Closing, the Company shall deliver to each of the Investors purchasing Shares and Warrants for cash at such initial closing, a certification in book-entry form representing such number of Shares and Warrants as is set forth opposite such Investor’s name on Schedule A hereto against receipt of a check subject to collection or a wire transfer in immediately available funds of the purchase price, to an account designated by the Company.
C:
(b) Additional Closings. The Company shall have the right, on one or more occasions, to hold additional closings (each, an “Additional Closing,” and, collectively with the Initial Closing, the “Closings,” and individually, a “Closing”), pursuant to which it shall have the right to issue and sell additional Shares to additional Investors or existing Investors. At each Additional Closing, the Company shall deliver to each Investor purchasing Shares and Warrants at such additional closing, a certification in book-entry form representing such number of Shares and Warrants as is set forth opposite such Investor’s name on Schedule A hereto against receipt of a check subject to collection or a wire transfer in immediately available funds of the purchase price, to an account designated by the Company. By receiving Shares and Warrants at an Additional Closing, each Investor so receiving Shares and Warrants thereby represents that its representations and warranties contained in Section 3 are true and correct as of the date of such Additional Closing.
The obligation of each Investor to purchase and pay cash for the Shares and Warrants to be delivered at a Closing is, unless waived by such Investor, subject to the condition that the Company’s representations and warranties contained in Section 2 are true, complete and correct on and as of such Closing date. The obligation of the Company to sell and issue Shares to be delivered at a Closing is, unless waived by the Company, subject to the condition that the relevant Investor’s representations and warranties contained in Section 3 are true, complete and correct on and as of the Closing Date.
Section 2 - Representations and Warranties
of the Company
The Company represents and warrants to each Investor as follows:
2.1 Existence of Company. The Company is a duly organized Delaware corporation. The Company is validly existing in all jurisdictions where it conducts its business.
2.2 Authority to Execute. The execution, delivery and performance by the Company of this Agreement and the issuance of the Shares and Warrants are within the Company’s corporate powers, have been duly authorized by all necessary corporate action, do not and will not conflict with any provision of law or organizational document of the Company (including its Certificate of Incorporation or Bylaws) or of any agreement or contractual restrictions binding upon or affecting the Company or any of its property and need no further stockholder or creditor consent.
2.3 No Stockholder Approval Required. No approval of the Company’s stockholders is required for (i) the entry by the Company into this Agreement, or (ii) the issuance of the Shares and Warrants contemplated by this Agreement.
2.4 Warrants. The form of Warrant is attached hereto as Schedule B and will conform in all respects to the terms thereof.
2.5 Valid Issuance. The Shares will be, validly issued, fully paid and nonassessable and each of the Shares and the Warrants will be free of restrictions on transfer other than restrictions on transfer under, applicable state and federal securities laws and liens or encumbrances created by or imposed by the Investor. Assuming the accuracy of the representations of the Investor in Section 3 of this Agreement, and the Shares and the Warrants will be issued in compliance with all applicable federal and state securities laws.
C:
| C: 2 |
2.6 Binding Obligation. Each of this Agreement and the Warrants is, a valid and binding obligation of the Company enforceable against the Company in accordance with its terms, subject, as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’ rights generally and to general equitable principles.
2.7 Litigation. No litigation or governmental proceeding is pending or threatened against the Company which may have a materially adverse effect on the financial condition, operations or prospects of the Company, and to the knowledge of the Company, no basis therefore exists.
2.8 Intellectual Property. To the best of the Company’s knowledge, the Company owns or possesses sufficient legal rights to all patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes necessary for its business as now conducted and as presently proposed to be conducted, without any known infringement of the rights of others. There are no outstanding options, licenses or agreements of any kind relating to the foregoing proprietary rights, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information and other proprietary rights and processes of any other person or entity other than such licenses or agreements arising from the purchase of “off the shelf” or standard products.
2.9 SEC Reports. The Company has filed all forms, reports, schedules, proxy statements, registration statements and other documents (including all exhibits thereto) required to be filed by it with the U.S Securities and Exchange Commission (the “SEC”) pursuant to the federal securities laws and the SEC rules and regulations thereunder, together with all certifications required pursuant to the Sarbanes-Oxley Act of 2002 (the “Sarbanes-Oxley Act”) (as they have been amended since the time of their filing, including all exhibits thereto, the “SEC Reports”). Each of the SEC Reports complied in all material respects with the applicable requirements of the Securities Act of 1933, as amended (the “Securities Act”) and the Securities Exchange Act of 1934, as amended, the Sarbanes-Oxley Act and the rules and regulations of the SEC under all of the foregoing. None of the SEC Reports contained any untrue statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading.
C:
| 3 |
Section 3 - Representations and Warranties
of the Investors
Each Investor represents and warrants to the Company as follows:
3.1 Authorization; Binding Obligations; No Violation. The Investor has full power and authority to enter into this Agreement and this Agreement constitutes a valid and legally binding obligation of the Investor, enforceable against the Investor in accordance with its terms, subject, as to enforcement of remedies, to applicable bankruptcy, insolvency, moratorium, reorganization and similar laws affecting creditors’ rights generally and to general equitable principles. The execution and delivery by the Investor of this Agreement, the consummation of the transactions contemplated hereby and thereby, and the compliance by the Investor with the terms and provisions hereof and thereof, will not result in a default under (or give any other party the right, with the giving of notice or the passage of time, or both, to declare a default or accelerate any obligation under) or violate any charter or similar documents of the Investor, if other than a natural person, or any contract to which the Subscriber is a party or by which it or any of its properties or assets are bound, or violate any requirement of law applicable to the Investor.
3.2 Accredited Investor. The Investor is an “accredited investor” within the meaning of SEC Rule 501 of Regulation D promulgated under the Securities Act.
3.3 Investment for Own Account. The Shares and the Warrants are being acquired for his, her or its own account, for investment and not with a view to, or for resale in connection with, any distribution or public offering thereof within the meaning of the Securities Act.
3.4 Knowledge and Experience. The Investor has such knowledge and experience in financial and business matters that (s)he is capable of evaluating the merits and risks of an investment in the Shares and of making an informed investment decision with respect thereto, has the ability and capacity to protect his/her interests and can bear the economic risk of the acceptance of the Shares, including a total loss of his/her investment.
3.5 Opportunity to Ask Questions. The Investor has had the opportunity to ask questions and receive answers from the Company or any authorized person acting on its behalf concerning the Company and its business and to obtain any additional information, to the extent possessed by the Company (or to the extent it could have been acquired by the Company without unreasonable effort or expense) necessary to verify the accuracy of the information received by the Investor. In connection therewith, the Investor acknowledges that (s)he has had the opportunity to discuss the Company’s business, management and financial affairs with the Company’s management or any authorized person acting on its behalf.
3.6. Receipt of Information. The Investor has received and reviewed all of the information concerning the Company and the Shares and the Warrants, both written and oral, that the Investor desires. Without limiting the generality of the foregoing, the Investor has been furnished with or has had the opportunity to acquire, and to review: all information, both written and oral, that the Investor desires with respect to the Company’s business, management, financial affairs and prospects. In determining whether to make this investment, the Investor has relied solely on his/her own knowledge and understanding of the Company and its business and prospects based upon the Investor’s own due diligence investigations and the Company’s filings with the SEC.
3.7 Disqualification. No “bad actor” disqualifying event described in Rule 506(d)(1)(i)-(viii) of the Securities Act (a “Disqualification Event”) is applicable to the Investor or, to the Investor's knowledge, any Covered Person (as hereinafter defined), except for a Disqualification Event as to which Rule 506(d)(2)(ii–iv) or (d)(3), is applicable. “Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated under the Securities Act, any individual listed in the first paragraph of Rule 506(d)(1) of the Securities Act.
C:
| 4 |
Section 4 - Miscellaneous
4.1 No Waiver; Cumulative Remedies. No failure or delay on the part of any party to this Agreement in exercising any right or remedy under, or pursuant to, this Agreement shall operate as a waiver thereof, nor shall any single or partial exercise of any such right, remedy or power preclude other or further exercise thereof, or the exercise of any other right, remedy or power. The remedies in this Agreement are cumulative and are not exclusive of any remedies provided by law.
4.2 Amendments and Waivers. Except as otherwise expressly set forth in this Agreement, any term of this Agreement may be amended (either retroactively or prospectively) with the written consent of the Company and Investors owning a majority of the Shares purchased in the Offering Majority Holders. Any amendment effected in accordance with this Section 4.2 shall be binding upon each Investor, each future holder of Shares and the Company.
4.3 Notices, Etc. All notices, requests, consents and other communications hereunder to any party shall be deemed to be sufficient if contained in a written instrument delivered in person; sent by facsimile transmission; sent by electronic mail; duly sent by first class registered or certified mail, return receipt requested, postage prepaid; or duly sent by overnight delivery service (e.g., Federal Express) addressed to such party (i) if to the Company, at the address, fax number or electronic mail address, as applicable, set forth on the signature page hereof or (ii) if to an Investor, at the address, fax number or electronic mail address, as applicable, set forth on Schedule A hereto, or at such other address, fax number or electronic mail address as may hereafter be designated in writing by the addressee to the sender. All such notices, advises and communications shall be deemed to have been received: (a) in the case of personal delivery, on the date of such delivery; (b) in the case of facsimile or electronic mail transmission, on the date of transmission; and (c) in the case of mailing or delivery by service, on the date of delivery as shown on the return receipt or delivery service statement.
4.4 Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law provisions of the State of Delaware or of any other state. The Company and each Investor consent to personal jurisdiction in New York County, New York.
4.5 Severability. If any term in this Agreement is held to be illegal or unenforceable, the remaining portions of this Agreement shall not be affected, and this Agreement shall be construed and enforced as if this Agreement did not contain the term held to be illegal or unenforceable.
4.6 Binding Effect. This Agreement shall be binding upon and inure to the benefit of the Company and each Investor and their respective successors and assigns.
C:
| 5 |
4.7 Transfer of Shares and Warrants. Notwithstanding the legend required to be placed on the Shares and Warrants by applicable law, no registration statement or opinion of counsel shall be necessary: (a) for a transfer of Shares and Warrants to the respective estate of each Investor or for a transfer of Shares and Warrants by gift, will or intestate succession of each Investor to his or her spouse or to the siblings, lineal descendants or ancestors each Investor or his or her spouse, if the transferee agrees in writing to be subject to the terms hereof to the same extent as if he or she were the original Investor hereunder; or (b) for a transfer of Shares and Warrants pursuant to SEC Rule 144 or any successor rule, or for a transfer of Shares and Warrants pursuant to a registration statement declared effective by the SEC under the Securities Act relating to the Shares and Warrants.
4.8 Survival of Representations, Warranties and Covenants. The representations and warranties of the parties contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement indefinitely, and shall in no way be affected by any investigation of the subject matter thereof made by or on behalf of the other parties. The covenants of the parties contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement until such time as the Notes have been paid in full.
4.9 Entire Agreement. This Agreement the Warrant constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral agreement relating to the subject matter hereof existing between the parties are expressly canceled.
4.10 Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be an original but all of which together shall constitute one and the same instrument.
4.11 California Commissioner of Corporations. THE SALE OF THE SHARES AND WARRANTS WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF THE SHARES AND WARRANTS OR PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION FOR SUCH SHARES AND WARRANTS PRIOR TO THE QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SHARES IS EXEMPT FROM QUALIFICATIONS BY SECTION 25100, 25102 OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO EXEMPT.
[Remainder of Page Intentionally Left Blank]
C:
| 6 |
IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed and delivered by their proper and duly authorized officers as of the date first written above.
| MYND ANALYTICS, INC. | ||
| By: | ||
| Name: Donald D'Ambrosio | ||
| Title: Chief Financial Officer | ||
Address/Fax Number/E-mail Address for Notice:
26522 La Alameda
Mission Viejo, CA 92691
Fax: (866) 867 4446
| INVESTOR: | ||
| By: | ||
| Name: | ||
| Title: | ||
[SIGNATURE PAGE TO SUBSCRIPTION AGREEMENT]
C:
SCHEDULE A
| Name, Address, Fax Number, E-Mail Address and Tax ID Number of Investor |
Aggregate Purchase Price |
|
Name:_________________________________
Address:_______________________________
______________________________________
Fax:__________________________________
Email:_________________________________
Tax ID:________________________________
|
(A) Quantity of Shares and Warrants: ___,___
(B) Price per Share and Warrant: $1.85
Aggregate Purchase Price (A) x (B):
$______________________ |
| TOTAL: |
C:
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 12/11/18 | |||
| For Period end: | 9/30/18 | |||
| 9/21/18 | 8-K | |||
| 9/20/18 | ||||
| List all Filings | ||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/31/23 Emmaus Life Sciences, Inc. 10-K 12/31/22 88:18M Donnelley … Solutions/FA 3/31/22 Emmaus Life Sciences, Inc. 10-K 12/31/21 98:18M ActiveDisclosure/FA 8/10/21 Emmaus Life Sciences, Inc. 10-K/A 12/31/20 92:18M ActiveDisclosure/FA 5/04/21 Emmaus Life Sciences, Inc. 10-K 12/31/20 97:18M ActiveDisclosure/FA 1/25/21 Emmaus Life Sciences, Inc. 10-K 12/31/19 121:29M ActiveDisclosure/FA 5/30/19 SEC UPLOAD¶ 6/27/19 2:45K Emmaus Life Sciences, Inc. 5/02/19 SEC UPLOAD¶ 6/27/19 2:53K Emmaus Life Sciences, Inc. |